UK firm unveils respiratory apps
pharmafile | April 21, 2015 | News story | Medical Communications, Sales and Marketing | Activ8rlives, Aseptika, SENSOR, communications, digital
Cambridgeshire-based healthcare tech firm Aseptika has made its suite of apps available to support studies in respiratory research.
The UK firm that manufactures a range of tests and diagnostic devices under its Activ8rlives brand, has developed its offerings for people with long-term respiratory conditions who want to self-monitor and self-manage their health at home.
Its SENSOR suite of apps was designed and trialled in collaboration with an NHS Trust in a clinical trial funded by NHS England, which has just been completed in Hampshire, through a Small Business Research Initiative (SBRI) Healthcare programme.
Kevin Auton, the managing director of Aseptika says: “The release of the SENSOR I App via the Apple Store is an important milestone for Aseptika. It supports the increasing use of self-monitoring at home by the patient as policy makers shift the balance of care from hospitals to the home and the community throughout the EU.”
The app which is free to download was designed for use by people of any age but is especially inclusive for older patients. The colourful user interface, step-by-step instructions and motivational messages enable the user to collect 40 vital signs and questions about their daily health, all in less than 10 minutes per day.
The volunteer patients measure on a daily basis: lung function by simple spirometry, blood oxygen saturation, blood pressure, heart rate, levels of physical activity and body composition – alongside a number of questions capturing the data routinely requested in paper-based questionnaires.
The firm’s SENSOR I App collects and displays the data on that day for the key vital signs to the user, but the user is ‘blinded’ to the longitudinal data – which is useful in clinical research studies.
These data are simultaneously uploaded to Activ8rlives’ web-servers for review as a cohort by clinical teams through a clinician portal in Activ8rlives. The ownership of the data is retained by the user at all times, but can be shared (by permission of the user) with care workers, supporters and family who are involved in their care.
The SENSOR II app from the company will be released shortly in which users in future randomised controlled trials are unblinded to their longitudinal data, which is displayed as charts and bar charts as they record their vital signs on a daily basis to enable them to self-monitor and self-manage their respiratory disease at home – and to watch for signs of impending ill health associated with respiratory exacerbations.
Auton adds: “The SENSOR App suite are tools which can be used to facilitate a new partnership between the patient and their clinical teams and complement the new Activ8rlives v3.0 app, which shares many of the same features as SENSOR but is designed for use by the consumer.”
Brett Wells
Related Content
Virtual Inspections: Embracing the Digital Change
Virtual inspections must become a part of companies’ repertoires if they aim to maintain quality …
COVID-19 is pushing healthcare firms to embrace digital transformation, reports suggest
The COVID-19 pandemic forced industries across the board to evolve or die with regard to …
Government appoints health minister from firm trying to win NHS contracts
The British Government has come under fire over the appointment of former Tory MP, Nicola …
